This study incorporates fundamental research referring to considerable amounts of gene-sequencing data and bioinformatics tools to analyze the pathological mechanisms of DLBCL.
Bone-protecting agents reduce the risk of bone fractures in patients with mCRPC who receive enzalutamide, with or without radium-223, according to results from a phase 3 trial.
Phase 2 data show a progression-free survival benefit with the combination of pasireotide and everolimus in patients with advanced neuroendocrine tumors of the lung or thymus.
Study investigators aim to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.
The phase III CheckMate 649 trial shows that the addition of first-line nivolumab to CT results in improved overall and PFS among patients with advanced HER2- gastric, GEJ, and...
Clinical management of soft tissue sarcoma is particularly challenging. Here, investigators use digital pathology and deep learning for diagnosis and prognosis prediction of STS.